Abstract
Liarozole binds to the cytochrome P-450-dependent hydroxylating enzymes involved in steroid biosynthesis and retinoic acid catabolism. This phase I study investigated the clinical/endocrine toxicity profile of liarozole and determined the maximally tolerated dose (MTD) in hormone-refractory prostate cancer patients. Groups of five patients were treated with oral liarozole caplets, starting at 37.5 mg twice daily. The dose was doubled for each subsequent group until the MTD was reached, after which, an additional 18 patients were entered into the MTD-1 dose stratum. The long-term safety of liarozole was assessed based on treatment-emergent signs and symptoms and clinically significant laboratory results. Thirty-eight patients were enrolled. The MTD was determined to be 300 mg twice daily. Side effects that defined the MTD included lethargy, somnolence, body rash, and paresthesias. Two deaths occurred during the trial (pneumonia and myocardial infarction). Four patients had a > 50% decrease in prostate-specific antigen (PSA) levels (two at 150 mg, two at 300 mg). Of nine patients with measurable disease, two had partial responses. Liarozole was generally well tolerated with no evidence of adrenal insufficiency. Preliminary eviden...Continue Reading
References
Apr 12, 1979·The New England Journal of Medicine·L A Klein
Aug 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A RitterT J Kinsella
Sep 1, 1992·The Journal of Steroid Biochemistry and Molecular Biology·R De CosterC Bowden
Feb 19, 1992·Journal of the National Cancer Institute·S M LippmanW K Hong
Jan 1, 1990·The Prostate·R Van GinckelW Distelmans
Aug 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D L TrumpV C Jordan
Dec 1, 1987·The American Journal of Medicine·A P Lyss
Jan 1, 1988·Cancer Chemotherapy and Pharmacology·C F RochlitzE C Cadman
Jul 1, 1983·The Journal of Urology·J TrachtenbergA Pont
Aug 1, 1984·Cancer·N H SlackG P Murphy
Apr 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A SellaC J Logothetis
Mar 1, 1993·The Journal of Urology·W K Kelly, H I Scher
Apr 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W K KellyS D Fossa
Aug 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H I Scher, W K Kelly
Jan 1, 1994·CA: a Cancer Journal for Clinicians·C C BoringS Montgomery
Jan 1, 1993·CA: a Cancer Journal for Clinicians·C C BoringT Tong
Sep 1, 1955·British Journal of Cancer·I LASNITZKI
Citations
Jun 9, 2000·Breast Cancer Research and Treatment·A HamiltonJ Klijn
Apr 7, 2000·Breast Cancer Research and Treatment·P E GossL M Tye
Nov 3, 2016·Cancer Immunology Research·Hweixian Leong PennyEdgar G Engleman
Feb 23, 2021·Frontiers in Oncology·Ruochen LiuHongjuan Cui